Summary:
A retrospective clinical review found that adults with drug-resistant epilepsy who used recreational cannabis nearly every day experienced more than twice the annual rate of convulsive (tonic–clonic) seizures compared with nonusers. Frequent users also reached drug-resistant status and required specialized inpatient monitoring much faster—on average within five years of their first seizure versus 18 years for nonusers. Structural brain scans in these frequent users were often normal, suggesting functional circuit disruption related to cannabinoid receptor activity rather than clear tissue scarring.
Key Facts:
- Double the Convulsive Seizures: Near-daily cannabis users recorded over twice the annual frequency of generalized tonic–clonic seizures compared with nonusers, with about 90% of frequent users experiencing these high-risk events versus roughly 50% of nonusers.
- Faster Progression to Drug Resistance: Patients using cannabis 20 or more days per month progressed to a drug-resistant state and inpatient epilepsy monitoring in a mean of 5 years after first seizure, compared with an 18-year mean in nonusers.
- Lack of Typical Structural Damage: Although severe, drug-resistant epilepsy often produces visible hippocampal scarring, frequent cannabis users in this cohort typically had largely normal MRI scans, pointing toward functional network changes rather than overt structural lesions.
Source: Washington University School of Medicine in St. Louis
As recreational cannabis access and high-potency products become more widespread, neurologists report a rising clinical pattern: young adults presenting with severe, intractable seizures despite lacking traditional risk factors. Although pharmaceutical-grade cannabidiol (CBD) is approved for certain pediatric epilepsies, the wider recreational market is dominated by high-THC products that may have different effects on neural circuits. This study, led by teams at Washington University School of Medicine in St. Louis and the University of Wisconsin School of Medicine and Public Health and published in Epilepsia, examined whether frequent recreational cannabis use was associated with worse epilepsy outcomes among adults admitted to an epilepsy monitoring unit (EMU).
Faster Onset of Drug Resistance and Elevated Convulsive Seizures
Researchers reviewed clinical records for 64 adults with drug-resistant epilepsy—defined as ongoing seizures despite adequate trials of at least two appropriate antiseizure medications—admitted to a tertiary EMU between 2019 and 2024. Patients were categorized as frequent users (cannabis use on ≥20 days per month) or nonusers. Low-use patients were excluded from analysis.
Key comparisons between 22 frequent recreational users and 42 nonusers revealed substantial differences in seizure severity and clinical course:
- Higher Frequency of Convulsive Events: Frequent users had more than double the annual rate of focal-to-bilateral tonic–clonic seizures (FBTCS) compared with nonusers, and about 90% of frequent users experienced generalized tonic–clonic seizures versus roughly 57% of nonusers.
- Accelerated Disease Progression: The interval from first seizure to EMU admission averaged 5.0 years for frequent users versus 18.1 years for nonusers, indicating much faster progression to drug-resistant epilepsy among frequent cannabis users.
- Greater Medication Burden: Despite a shorter duration of epilepsy, frequent users were discharged on a higher number of concurrent antiseizure medications, reflecting increased treatment complexity.
“I was seeing patients with severe, disabling seizures who didn’t have the expected risk factors,” said Aaron F. Struck, MD, associate professor of neurology at WashU Medicine. “They shared frequent, high-potency cannabis use, an uncontrolled variable increasingly present in practice but previously understudied.”
Distinguishing THC from Antiseizure Cannabinoids
The study highlights the pharmacological difference between regulated, pharmaceutical cannabinoids and unregulated recreational products. Clinical-grade CBD approved by the U.S. FDA for specific childhood epilepsies is nonpsychoactive and contains negligible THC. Preclinical data indicate CBD can have anticonvulsant effects, whereas Δ9‑tetrahydrocannabinol (THC), a partial agonist at CB1 receptors, can under some conditions be proconvulsant. Modern recreational products often contain high THC and minimal CBD, a composition that may alter seizure risk or disease trajectory.
To test whether cannabis use represented self-medication in response to existing seizures, the team examined timelines for 15 frequent users with complete histories. All 15 reported initiating regular cannabis use before their first documented clinical seizure, weakening the hypothesis that use was exclusively a response to epilepsy.
Functional Circuit Miswiring vs. Physical Scarring
Typically, epilepsy that becomes drug-resistant and severe is associated with structural changes such as hippocampal sclerosis visible on MRI. In contrast, most frequent cannabis users in this cohort had largely normal structural imaging. Because CB1 receptors are densely expressed in hippocampal and temporal lobe circuits—regions commonly implicated in seizure generation—the authors propose that chronic high-dose THC exposure could disrupt circuit balance and neuronal firing patterns without leaving obvious macroscopic lesions. This mechanistic idea remains hypothetical and requires targeted investigation.
The authors emphasize that the findings are observational and demonstrate association, not causation. To determine whether reducing or stopping cannabis use improves seizure outcomes, the team is planning prospective, multisite studies that will use objective toxicology testing rather than self-report.
“When patients ask whether their cannabis use is affecting their seizures, we can’t yet give a definitive answer,” said Santiago Philibert-Rosas, MD. “Larger, controlled studies will clarify how much use matters and whether cessation changes the course of disease, enabling informed clinical decisions.”
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full for accuracy.
- Additional context was provided by staff editors.
About this epilepsy Research:
- Media Contact: Abeeha Shamshad
- Source: WUSTL (Washington University School of Medicine in St. Louis)
- Image Credit: Image credited to Neuroscience News
- Original Research (Open Access): Epilepsia (Sept 22, 2026). Title: “Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy.” Authors include Santiago Philibert-Rosas and colleagues. DOI: 10.1002/epi.70456
Abstract
Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy
Objective
Cannabis use has increased substantially, and contemporary products often have high THC concentrations with variable cannabinoid profiles. The link between frequent recreational cannabis use and epilepsy outcomes in adults is not well established. This study evaluated associations between frequent cannabis use and clinical severity, seizure phenotype, and imaging characteristics among patients admitted to an EMU.
Methods
This retrospective cohort included adults with drug-resistant epilepsy admitted to a tertiary EMU. Cannabis use documented in the medical record over the year before admission classified patients into frequent users (≥20 days/month) and nonusers; those reporting low use were excluded. Primary outcomes were time from epilepsy onset to EMU admission, presence and frequency of focal-to-bilateral tonic–clonic seizures (FBTCS), and antiseizure medication burden. Secondary analyses examined epilepsy syndrome and mesial temporal lobe volumes.
Results
Sixty-four patients met inclusion criteria (42 nonusers, 22 frequent users). Frequent cannabis use correlated with a shorter time from epilepsy onset to EMU admission (mean 5.0 vs. 18.1 years, p = .004), higher prevalence of FBTCS (90.9% vs. 57.1%, p = .04), greater annualized FBTCS frequency (mean 3.00 vs. 1.32 per year, p = .003), and higher antiseizure medication burden (mean 3.05 vs. 2.21 concurrent medications, p = .027). All frequent users had temporal lobe epilepsy, although the difference in temporal lobe epilepsy prevalence between groups was not statistically significant. Imaging analyses found no significant group differences.
Significance
In this EMU cohort of adults with drug-resistant epilepsy, frequent recreational cannabis use was associated with markers of increased epilepsy severity—greater FBTCS burden, faster progression to specialized evaluation, and higher medication requirements. Prospective studies that use objective measures of cannabis exposure are needed to clarify the relationship and inform clinical guidance.